Evolus Stock Price, News & Analysis

Evolus reported Q4 2021 net revenue of $34.7 million, a 68% increase year-over-year. Full-year 2021 revenue reached $99.7 million, up 76% from 2020. The company reaffirmed guidance for 2022 revenues between $143 million and $150 million, projecting growth of 43% to 50%. Evolus added 400 new customer accounts in Q4 and achieved significant marketing successes, including over 1 billion impressions. Despite losses from operations reducing by 83%, the company is on track for growth, aiming for better profit margins post-settlement royalty reductions in September 2022.

Evolus, Inc. (NASDAQ: EOLS) announces the retirement of Chief Financial Officer Lauren Silvernail, effective May 31, 2022, after nearly four years with the company. During her tenure, she significantly contributed to the company's growth, leading efforts in commercial infrastructure and balance sheet restructuring. Silvernail also negotiated a $125 million credit facility to support the company through cash flow breakeven, positioning Evolus for future success. The search for her successor is already underway.

Evolus, Inc. (NASDAQ: EOLS) announced the appointment of Christos Monovoukas as Senior Vice President of Corporate Development, effective February 28, 2022. Monovoukas has over 20 years of experience in business development, previously serving at Olympus Corporation and Smith & Nephew. In connection with his hiring, Evolus granted him inducement awards consisting of options for 171,103 shares and 39,012 RSUs, with an exercise price of $9.15. CEO David Moatazedi expressed confidence in Monovoukas' ability to support the company's growth strategy.

Evolus, Inc. (NASDAQ: EOLS) announced it will report its fourth quarter and year-end 2021 financial results on March 3, 2022, after U.S. market close. A conference call and live webcast will follow at 4:30 p.m. ET, including a Q&A session. Participants can join via phone or through the Evolus website. A replay of the call will be available after completion. Evolus, known for its neurotoxin Jeuveau®, focuses on redefining the aesthetic market with innovative customer-centric products.

Evolus, Inc. (NASDAQ: EOLS) has announced that its submission for regulatory approval of Nuceiva® (prabotulinumtoxinA) has been accepted by the Australian Therapeutics Good Administration (TGA). This is a significant milestone for the company's international growth strategy, as Australia represents one of the largest global markets for aesthetics. Nuceiva® is already approved in the U.S. as Jeuveau®, and in Europe and Canada. Evolus aims to complete the TGA approval process in 2023 and plans to launch Nuceiva® in select European countries later this year.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, announced participation in the Virtual 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, from 4:20 PM to 4:50 PM ET. The event will showcase Evolus' focus on delivering breakthrough products, including its FDA-approved neurotoxin, Jeuveau^®. Interested parties can access an audio webcast on the investor relations section of Evolus’ website, with a replay available for 90 days.

Evolus, Inc. (NASDAQ: EOLS) reported preliminary unaudited net revenues of approximately $34.7 million for Q4 2021, marking a 68% increase from the previous year. For full-year 2021, total net revenues reached approximately $99.7 million, a 76% growth over 2020. The company expects 2022 revenues between $143 million and $150 million, anticipating growth of 43% to 50%. As of December 31, 2021, Evolus maintains a strong cash position of $146.3 million. The company plans to enhance market presence and launch new products in 2022.

Evolus, Inc. (NASDAQ: EOLS) has appointed Brady Stewart, a digital and beauty innovator, to its Board of Directors, enhancing its leadership team. Stewart brings over 20 years of experience in digital innovation and direct-to-consumer strategies, currently serving as Chief Commercial Officer at Forma Brands. The Chairman, Vikram Malik, emphasized her potential contribution as the company aims to be a leading multi-product aesthetics company. Stewart expressed her excitement to join at a pivotal moment, highlighting the potential of the company's product, Jeuveau®, in transforming the aesthetic neurotoxin industry.

Tenaya Therapeutics (NASDAQ: TNYA) announced two key appointments: Karah Parschauer to its Board of Directors and Joanna Auch as Senior VP of People and Culture. These appointments aim to strengthen Tenaya's leadership amid its transition to a public company with over 100 employees. CEO Faraz Ali highlighted that both individuals bring valuable experience and will enhance the company's capabilities in drug development for heart disease. Parschauer has extensive biopharmaceutical experience and previously held roles at Ultragenyx, while Auch has over 15 years in HR.